Mirum Pharmaceuticals, Inc.
MIRM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $133,010 | $127,785 | $111,585 | $99,414 |
| % Growth | 4.1% | 14.5% | 12.2% | – |
| Cost of Goods Sold | $25,537 | $23,421 | $23,018 | $22,780 |
| Gross Profit | $107,473 | $104,364 | $88,567 | $76,634 |
| % Margin | 80.8% | 81.7% | 79.4% | 77.1% |
| R&D Expenses | $42,960 | $46,067 | $46,044 | $44,026 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $61,910 | $63,286 | $57,706 | $56,830 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $104,870 | $109,353 | $103,750 | $100,856 |
| Operating Income | $2,603 | -$4,989 | -$15,183 | -$24,222 |
| % Margin | 2% | -3.9% | -13.6% | -24.4% |
| Other Income/Exp. Net | $40 | -$470 | $1,535 | -$144 |
| Pre-Tax Income | $2,643 | -$5,459 | -$13,648 | -$24,366 |
| Tax Expense | -$262 | $402 | $1,029 | -$576 |
| Net Income | $2,905 | -$5,861 | -$14,677 | -$23,790 |
| % Margin | 2.2% | -4.6% | -13.2% | -23.9% |
| EPS | 0.057 | -0.12 | -0.3 | -0.49 |
| % Growth | 147.8% | 60% | 38.8% | – |
| EPS Diluted | 0.05 | -0.12 | -0.3 | -0.49 |
| Weighted Avg Shares Out | 58,101 | 49,727 | 48,889 | 48,338 |
| Weighted Avg Shares Out Dil | 56,994 | 49,727 | 48,889 | 48,338 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3,033 | $3,023 | $3,204 |
| Interest Expense | $355 | $3,589 | $3,596 | $3,579 |
| Depreciation & Amortization | $6,062 | $6,056 | $6,052 | $6,056 |
| EBITDA | $9,060 | $4,186 | -$4,000 | -$14,731 |
| % Margin | 6.8% | 3.3% | -3.6% | -14.8% |